Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
JUPITER, FL / ACCESS Newswire / January 27, 2026 /Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.
Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about Jupiter Neurosciences at www.jupiterneurosciences.com.
Event Details:
Conference: 3rd Annual DealFlow Discovery Conference
Venue: The Borgata Hotel, Casino & Spa
Location: Atlantic City, NJ
Date: January 28-29, 2026
Investors interested in scheduling a meeting with the Jupiter Neurosciences management team should request an investor pass to attend the conference (no cost to attend).
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter 's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company 's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson 's disease, including indications such as Alzheimer 's Disease, Mucopolysaccharidoses Type I, Friedreich 's Ataxia, and MELAS.
Media Contact:
Christer Rosén
Chairman and CEO
Jupiter Neurosciences, Inc.
IR@jupiterneurosciences.com
SOURCE: DealFlow Events
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
